default author photo

Keith Joseph Chappell

University of Queensland - School of Chemistry and Molecular Biosciences

St. Lucia

Brisbane

Australia

SCHOLARLY PAPERS

4

DOWNLOADS

578

TOTAL CITATIONS

4

Scholarly Papers (4)

1.

First Report of a Phase 1 Randomised Trial of Molecular Clamp-Stabilised Spike Protein-Based and MF59-Adjuvanted Vaccine for SARS-CoV-2

Number of pages: 37 Posted: 01 Feb 2021
University of Queensland - School of Chemistry and Molecular Biosciences, University of Melbourne - Department of Microbiology and Immunology (DMI), Australian National University (ANU) - Department of Immunology and Infectious Disease, University of Queensland - School of Chemistry and Molecular Biosciences, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland, University of Queensland - Australian Institute for Bioengineering and Nanotechnology (AIBN), Tanawell Consulting, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Queensland - TetraQ, University of Queensland - TetraQ, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, Burnet Institute, Burnet Institute, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), Australian National University (ANU) - Department of Immunology and Infectious Disease, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Queensland - Institute for Molecular Bioscience, University of Queensland - School of Chemistry and Molecular Biosciences and University of Queensland - School of Chemistry and Molecular Biosciences
Downloads 414 (176,035)
Citation 2

Abstract:

Loading...

2.

Long-Term Safety and Immunogenicity of an MF59-Adjuvanted Spike Glycoprotein-Clamp Vaccine for SARS-CoV-2 in Adults Aged 18–55 Years or ≥56 Years: 12-Month Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 1 Trial

Number of pages: 51 Posted: 28 Mar 2023
University of Queensland - School of Chemistry and Molecular Biosciences, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Melbourne, Australian National University (ANU) - Department of Immunology and Infectious Disease, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Medicine, Tanawell Consulting, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), Agilex Biolabs, Agilex Biolabs, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - Department of Microbiology and Immunology (DMI), Australian National University (ANU) - Department of Immunology and Infectious Disease, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Queensland - Institute for Molecular Bioscience, University of Queensland - School of Chemistry and Molecular Biosciences and University of Queensland - School of Chemistry and Molecular Biosciences
Downloads 78 (816,709)

Abstract:

Loading...

Clinical trial, phase 1, COVID-19 vaccine, Severe acute respiratory syndrome coronavirus 2, Spike protein, SARS-CoV-2, Molecular clamp

3.

Rapid Application of the Molecular Clamp Platform for SARS-CoV-2

Number of pages: 65 Posted: 24 Nov 2020
University of Queensland - Institute for Molecular Bioscience, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Melbourne - Department of Microbiology and Immunology (DMI), Australian National University (ANU) - Department of Immunology and Infectious Disease, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, Viroclinics Xplore, Viroclinics Xplore, Viroclinics Xplore, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland - Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland - Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland - Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland - Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland - Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland - Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland - Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland - Australian Institute for Bioengineering and Nanotechnology (AIBN), CSIRO Manufacturing, CSIRO Manufacturing, CSIRO Manufacturing, CSIRO Manufacturing, CSIRO Manufacturing, CSIRO Manufacturing, CSIRO Manufacturing, CSIRO Manufacturing, University of Queensland - TetraQ, StageBio, University of Queensland - Centre for Advanced Materials Processing and Manufacturing, University of Queensland - TetraQ, University of Queensland - TetraQ, University of Melbourne - Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity - WHO Collaborating Centre for Reference and Research on Influenza, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - Australian Infectious Diseases Research Centre, Utrecht University - Division of Pathology, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, Australian National University (ANU) - Department of Immunology and Infectious Disease, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences and University of Queensland - School of Chemistry and Molecular Biosciences
Downloads 57 (989,921)
Citation 2

Abstract:

Loading...

SARS-CoV-2, Molecular Clamp, subunit vaccine, rapid response, hamster protection, neutralising antibodies, polyfunctional T cells, cytotoxic CD8+ T cells, helper T cells, immune breadth

4.

Adaptive Evolution of KoRV-A Transcriptional Silencing in Wild Koalas

Number of pages: 37 Posted: 16 Oct 2024
University of Massachusetts Worcester - Program in Bioinformatics and Integrative Biology (BIB), University of Queensland, University of Massachusetts Worcester - UMass Chan Medical School, University of Massachusetts Worcester - UMass Chan Medical School, University of Massachusetts Worcester - UMass Chan Medical School, Tongji University, Tongji University, University of Massachusetts Medical School - Program in Molecular Medicine, University of Queensland - School of Chemistry and Molecular Biosciences, University of Massachusetts Worcester - Program in Bioinformatics and Integrative Biology (BIB), University of Massachusetts Worcester - Program in Molecular Medicine and Independent
Downloads 29 (1,332,057)

Abstract:

Loading...

Adaptive evolution, retroviral genome remodeling, koala retrovirus, piRNAs, transcriptional silencing